Senior Correspondent, London
Ben's Feed
Sep 11, 2014

Ebola highlights slow progress in war on tropical diseases

LONDON (Reuters) – Some of the world’s most gruesome diseases are finally getting a bit of attention.

The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.

Sep 11, 2014

Analysis – Ebola highlights slow progress in war on tropical diseases

LONDON (Reuters) – Some of the world’s most gruesome diseases are finally getting a bit of attention.

The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.

Sep 9, 2014
Sep 9, 2014
Sep 8, 2014
Sep 8, 2014

Cost a focus as GSK takes lead in new wave of biotech lung drugs

LONDON, Sept 8 (Reuters) – Cost-effectiveness is seen as a
challenge for a new group of biotech lung drugs that have
produced promising results in clinical tests, of which the first
is likely to be launched next year by GlaxoSmithKline.

Rival firms are racing to develop similar injectable drugs
for patients with severe asthma, who do not respond adequately
to traditional inhalers, in pursuit of a new market that
analysts believe may be worth around $7.5 billion in annual
sales.

Sep 8, 2014
Sep 4, 2014

J&J Ebola vaccine to start clinical trials in early 2015

Sept 4 (Reuters) – Scientists will fast-track tests on another Ebola vaccine, this time from Johnson & Johnson JNJ.N, in another sign that the world’s worst outbreak of the virus is mobilizing research into the deadly disease.

J&J said on Thursday that clinical trials of its new vaccine, which includes technology from Danish biotech firm Bavarian Nordic BAVA.CO, would commence in early 2015.

Sep 2, 2014
Sep 2, 2014

Exclusive: ‘Back to normal’ for AstraZeneca CEO, despite Pfizer rumors

BARCELONA (Reuters) – Though speculation is rife of a new Pfizer bid, AstraZeneca’s chief executive is not holed up with advisers in London or New York. Instead, he has spent the last three days immersed in heart science in Barcelona.

“The only thing I can tell you is I am here – and imagine where I would be if something was happening!” Pascal Soriot told Reuters on the sidelines of the European Society of Cardiology congress, the world’s largest heart meeting.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben